Takeda Pharmaceutical Co. Ltd.
Company Snapshot
Founded: 1781
Entity Type: Public
Employees: 50000
Region: U.S.
Revenue: $30242 Millions
Revenue Year: 2022
Segment: Gastroenterology (GI)
Headquarter: Tokyo, Japan
Corporate Address: 1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8668, Japan Tel. +81-3-3278-2111 www.takeda.com
Company Overview
Takeda Pharmaceutical Co. Ltd. is a global biopharmaceutical company headquartered in Japan. Takeda focuses on five key business areas: Gastroenterology, Rare Diseases, Plasma-Derived Therapeutics (PDT) Immunology, Oncology and Neuroscience. Takeda supports dedicated R&D efforts across three areas: Innovative Biopharma, PDT and Vaccines.
In January 2019, Takeda acquired Shire for an aggregate consideration of $62 billion. The acquisition of Shire significantly changed its business through, among other things, the significant expansion of its product portfolio and geographic presence.
Financial Highlights (FY 2022)
Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***
This information is available for BCC Research members only.
Company's Business Segments
- Gastroenterology (GI) : Ulcerative colitis or Crohn’s disease, Refractory complex perianal fistulas.
- Rare Diseases : Prevention of hereditary angioedema attacks, Post-transplant CMV infection.
- PDT immunology : Primary and secondary immunodeficiencies and multifocal motor neuropathy, Hypovolemia, hypoalbuminemia.
- Oncology : ALK-positive non-small cell lung cancer
- Neuroscience
- Others : Dengue diseas, Active immunization, COVID-19 and others
Applications/End User Industries
- Immunology
- Oncology
- Gastrointestinal
- Inflammatory Bowel
- Orphan
- Rare Genetic Disorders
- Plasma-Derived Therapies
- Immune System
- Autoimmune
- Oncology Therapies
- Chemotherapies
- Immunotherapies
- Pharmaceutical Research
BCC Research Beacon 